MDT

87.92

-0.94%↓

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

Home・Akcijų sąrašas・Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

76.49 2.11

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

74.12

Max

76.91

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-100M -229M
Pardavimai	46M 203M
Pelno marža	-112.808
Darbuotojai	1,402
EBITDA	4.7B 4.6B

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+29.34% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-04-29

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-1.4B 12B
Ankstesnė atidarymo kaina	74.38
Ankstesnė uždarymo kaina	76.49

Naujienos nuotaikos

By Acuity

50%

161 / 348 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Neutral Evidence

29.78 / 33.645 Palaikymas ir pasipriešinimas

Ionis Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-10 00:00; UTC

Svarbiausios naujienos

ADB: Higher Energy Prices to Raise Production, Consumer Costs

2026-04-10 00:00; UTC

Svarbiausios naujienos

ADB Projects Japan GDP Growth at 0.7% in 2026, 0.6% in 2027

2026-04-10 00:00; UTC

Svarbiausios naujienos

ADB Projects South Korea GDP Growth at 1.9% in 2026, 1.9% in 2027

2026-04-10 00:00; UTC

Svarbiausios naujienos

Extent of Slowdown Hinges on Duration of MidEast Conflict, ADB Says

2026-04-10 00:00; UTC

Svarbiausios naujienos

ADB Projects India GDP Growth at 6.9% in 2026, 7.3% in 2027

2026-04-10 00:00; UTC

Svarbiausios naujienos

ADB Projects China GDP Growth at 4.6% in 2026, 4.5% in 2027

2026-04-10 00:00; UTC

Svarbiausios naujienos

ADB Pojects Australia GDP Grrowth at 2.0% in 2026, 2.9% in 2027

2026-04-10 00:00; UTC

Svarbiausios naujienos

ADB Projects Taiwan GDP Growth at 7.6% in 2026, 4.0% in 2027

2026-04-10 00:00; UTC

Svarbiausios naujienos

Geopolitical Risks Make Asia's Economic Outlook Highly Uncertain, ADB Says

2026-04-10 00:00; UTC

Svarbiausios naujienos

Asia Regional Growth Likely to Moderate in 2026-2027, ADB Says

2026-04-09 23:44; UTC

Rinkos pokalbiai

Nikkei May Rise on Hopes for U.S.-Iran Talks -- Market Talk

2026-04-09 23:34; UTC

Rinkos pokalbiai

Gold Edges Lower Amid Lingering Inflation Concerns -- Market Talk

2026-04-09 23:14; UTC

Rinkos pokalbiai

Jefferies Upbeat on Australian Miners, But Recession a Key Risk -- Market Talk

2026-04-09 23:14; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-04-09 23:07; UTC

Rinkos pokalbiai

Centaurus's Supply Deal with Glencore Supports Jaguar Development -- Market Talk

2026-04-09 22:54; UTC

Rinkos pokalbiai

Transurban Lacks Appeal as Higher Fuel Prices Slow Traffic -- Market Talk

2026-04-09 22:31; UTC

Svarbiausios naujienos

Trump on Truth Social: 'That Is Not the Agreement We Have!'

2026-04-09 22:31; UTC

Svarbiausios naujienos

Trump on Truth Social: 'Iran Is Doing a Very Poor Job, Dishonorable Some Would Say, of Allowing Oil to Go Through the Strait of Hormuz'

2026-04-09 20:57; UTC

Svarbiausios naujienos

U.S. Oil Prices Are Back Near $100 After Israel Keeps Up Air Strikes on Lebanon -- Barrons.com

2026-04-09 20:55; UTC

Uždarbis

Stryker: Believes Incident Hasn't Had, and Isn't Reasonably Likely to Have, a Material Impact on 2026 Full-Year Guidance >SYK

2026-04-09 20:55; UTC

Uždarbis

Stryker: Determined Incident Had Material Impact on Operations, With Resulting Impact on Financial Results for 1Q >SYK

2026-04-09 20:55; UTC

Uždarbis

Stryker: Investigation of Cybersecurity Incident Remains Ongoing >SYK

2026-04-09 20:50; UTC

Rinkos pokalbiai

Energy & Utilities Roundup: Market Talk

2026-04-09 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-04-09 20:40; UTC

Įsigijimai, susijungimai, perėmimai

Blackstone Investment Positions Rowan to Continue Delivering Sustainable Data Center Capacity for World's Leading Technology Cos >BX

2026-04-09 20:39; UTC

Įsigijimai, susijungimai, perėmimai

Blackstone Blackstone Acquired Significant Minority Stake in Rowan Digital Infrastructure >BX

2026-04-09 20:39; UTC

Įsigijimai, susijungimai, perėmimai

Rowan Digital Infrastructure Announces Strategic Recapitalization

2026-04-09 20:25; UTC

Įsigijimai, susijungimai, perėmimai

SBA Communications Stock Soars on Buyout Interest. What It Means for Tower Stocks. -- Barrons.com

2026-04-09 20:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-04-09 19:30; UTC

Svarbiausios naujienos

How Digital Currencies Have Helped Iran -- WSJ

Akcijų palyginimas

Kainos pokytis

Ionis Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

29.34% į viršų

12 mėnesių prognozė

Vidutinis 96.98 USD 29.34%

Aukščiausias 120 USD

Žemiausias 72 USD

Remiantis 14 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Ionis Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

14 ratings

Pirkti

Laikyti

Parduoti

Remiantis 14 analitikų, pateikusių Ionis Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

29.78 / 33.645Palaikymas ir pasipriešinimas

The bullish and bearish events are balanced.

All events are bullish.

All events are bearish.

Rinkos nuotaikos

By Acuity

161 / 348 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.